FOAMIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Foamix Pharmaceuticals Ltd. - FOMX
NEW ORLEANS--(BUSINESS WIRE)--Nov 22, 2019--
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Foamix Pharmaceuticals Ltd. (NasdaqGS: FOMX ) to Menlo Therapeutics Inc. (NasdaqGS: MNLO). Under the terms of the proposed transaction, shareholders of Foamix will receive only 0.5924 shares of Menlo and one contingent stock right for each share of Foamix that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( firstname.lastname@example.org ) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-fomx/ to learn more.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191122005559/en/
CONTACT: Kahn Swick & Foti, LLC
Lewis S. Kahn
1100 Poydras St., Suite 3200
New Orleans, LA 70163
KEYWORD: UNITED STATES NORTH AMERICA LOUISIANA
INDUSTRY KEYWORD: LEGAL PROFESSIONAL SERVICES
SOURCE: Kahn Swick & Foti
Copyright Business Wire 2019.
PUB: 11/22/2019 08:04 PM/DISC: 11/22/2019 08:04 PM